Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.83 |
| ▸ | FAP | Q12884 | 6/20 | 0.71 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.71 |
| ▸ | HRH2 | P25021 | 1/20 | 0.71 |
| ▸ | MC4R | P32245 | 1/20 | 0.71 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.71 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.71 |
| ▸ | GHSR | Q92847 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576288 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL639988 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637493 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL3969508 | 0.94 | DPP4 (0.80) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL638362 | 0.94 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637386 | 0.94 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL16391894 | 0.94 | DPP4 (0.73) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637743 | 0.93 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL3548101 | 0.93 | DPP4 (0.73) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL636842 | 0.93 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879011-B2 | Amorphous form of linagliptin and process for preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2018-01-30 | — | — | US | claimed |
| US-20150051228-A1 | AMORPHOUS FORM OF LINAGLIPTIN AND PROCESS FOR PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2015-02-19 | — | — | US | claimed |
| WO-2024074612-A1 | A PHARMACEUTICAL INTERMEDIATE | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| US-9879011-B2 | Amorphous form of linagliptin and process for preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2018-01-30 | — | — | US | disclosed |
| US-9593119-B2 | Process for the preparation of dipeptidylpeptidase inhibitors | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-9522915-B2 | Method for preparing an important intermediate of linagliptin | 2Y-CHEM, LTD. (CN) | 2016-12-20 | — | — | US | disclosed |
| US-9522915-B2 | Method for preparing an important intermediate of linagliptin | 2Y-CHEM, LTD. (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20160272642-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | GLENMARK LIFE SCIENCES LIMITED (IN) | 2016-09-22 | — | — | US | disclosed |
| US-9353114-B2 | Process for the preparation of dipeptidylpeptidase inhibitors | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-9353114-B2 | Process for the preparation of dipeptidylpeptidase inhibitors | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | 2Y-CHEM, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | 2Y-CHEM, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-20150239887-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | GLENMARK GENERICS LIMITED (IN) | 2015-08-27 | — | — | US | disclosed |
| US-20150239887-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | GLENMARK GENERICS LIMITED (IN) | 2015-08-27 | — | — | US | disclosed |
| US-20150051228-A1 | AMORPHOUS FORM OF LINAGLIPTIN AND PROCESS FOR PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2015-02-19 | — | — | US | disclosed |
| WO-2013074817-A1 | SOLID STATE FORMS OF LINAGLIPTIN | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2013-05-23 | — | — | WO | disclosed |
| US-20130123282-A1 | SOLID STATE FORMS OF LINAGLIPTIN | METSGER LEONID (IL) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239887-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | DPP4, DPP9, DPP3 | DPP4 1/4885FAP 13/4885POU2F2 2898/4885 |
| US-20160272642-A1 | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | DPP9, DPP4, DPP7 | DPP4 2/4885FAP 19/4885POU2F2 3012/4885 |
| US-20150051228-A1 | AMORPHOUS FORM OF LINAGLIPTIN AND PROCESS FOR PREPARATION THEREOF | DPP4, PYGL, GID4 | DPP4 1/4885FAP 134/4885POU2F2 4164/4885 |
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | DPP4, DPP9, DPP3 | DPP4 1/4885FAP 19/4885POU2F2 1566/4885 |
| US-20130123282-A1 | SOLID STATE FORMS OF LINAGLIPTIN | DPP4, GLP1R, DPP3 | DPP4 1/4885FAP 249/4885POU2F2 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.